Resistance to FGFR1-targeted therapy leads to autophagy via TAK1/AMPK activation in gastric cancer

Background Fibroblast growth factor receptor 1 (FGFR1) is frequently dysregulated in various tumors. FGFR inhibitors have shown promising therapeutic value in several preclinical models. However, tumors resistant to FGFR inhibitors have emerged, compromising therapeutic outcomes by demonstrating mar...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2020-11, Vol.23 (6), p.988-1002
Hauptverfasser:	Peng, Rui, Chen, Yan, Wei, Liangnian, Li, Gang, Feng, Dongju, Liu, Siru, Jiang, Runqiu, Zheng, Shaojiang, Chen, Yun
Format:	Artikel
Sprache:	eng
Schlagworte:	Abdominal Surgery Adenocarcinoma - drug therapy AMP-Activated Protein Kinases - metabolism Animals Antineoplastic Agents - pharmacology Autophagy Autophagy - drug effects Benzamides - pharmacology Cancer Research Cell culture Cell Culture Techniques Cell Line, Tumor Drug resistance Drug Resistance, Neoplasm - genetics Epithelial-Mesenchymal Transition - drug effects Female Fibroblast growth factor receptor 1 Fibroblast growth factor receptors Gastric cancer Gastroenterology Gene expression Humans Kinases MAP Kinase Kinase Kinases - metabolism Medicine Medicine & Public Health Mesenchyme Metastases Metastasis Mice Mice, Inbred BALB C Molecular modelling Oncology Original Article Phagocytosis Piperazines - pharmacology Protein Kinase Inhibitors - pharmacology Pyrazoles - pharmacology Pyridines - pharmacology Pyrroles - pharmacology Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors Ribonucleic acid RNA Signal Transduction - drug effects Stomach Neoplasms - drug therapy Surgical Oncology TAK1 protein TOR protein Tumor cell lines Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!